MA43733A - Composés cinnolin-4-amine et leur utilisation pour traiter le cancer - Google Patents
Composés cinnolin-4-amine et leur utilisation pour traiter le cancerInfo
- Publication number
- MA43733A MA43733A MA043733A MA43733A MA43733A MA 43733 A MA43733 A MA 43733A MA 043733 A MA043733 A MA 043733A MA 43733 A MA43733 A MA 43733A MA 43733 A MA43733 A MA 43733A
- Authority
- MA
- Morocco
- Prior art keywords
- cinnolin
- amine compounds
- treat cancer
- cancer
- treat
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- DODZTSARNRLOKY-UHFFFAOYSA-N cinnolin-4-amine Chemical class C1=CC=C2C(N)=CN=NC2=C1 DODZTSARNRLOKY-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310883P | 2016-03-21 | 2016-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43733A true MA43733A (fr) | 2018-11-28 |
Family
ID=58361025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043733A MA43733A (fr) | 2016-03-21 | 2017-03-20 | Composés cinnolin-4-amine et leur utilisation pour traiter le cancer |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20190099421A1 (e) |
| EP (1) | EP3433251A1 (e) |
| JP (1) | JP2019512512A (e) |
| KR (1) | KR20180127419A (e) |
| CN (1) | CN108884084A (e) |
| AR (1) | AR107937A1 (e) |
| AU (1) | AU2017237394A1 (e) |
| BR (1) | BR112018068347A2 (e) |
| CA (1) | CA3017035A1 (e) |
| CO (1) | CO2018010951A2 (e) |
| DO (1) | DOP2018000197A (e) |
| IL (1) | IL261648A (e) |
| MA (1) | MA43733A (e) |
| MX (1) | MX2018011283A (e) |
| PE (1) | PE20181895A1 (e) |
| SG (1) | SG11201806982PA (e) |
| TW (1) | TW201808939A (e) |
| WO (1) | WO2017162605A1 (e) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111344293A (zh) * | 2017-09-20 | 2020-06-26 | 阿斯利康(瑞典)有限公司 | 1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途 |
| CA3093499A1 (en) * | 2018-03-14 | 2019-09-19 | Merck Patent Gmbh | Compounds and uses thereof to treat tumors in a subject |
| ES3001444T3 (en) * | 2018-09-14 | 2025-03-05 | Suzhou Zanrong Pharma Ltd | 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof |
| JP2023539715A (ja) | 2020-06-24 | 2023-09-19 | アストラゼネカ ユーケー リミテッド | 抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab, Soedertaelje | 4-anilinochinazolin derivate |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| CL2008000191A1 (es) * | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer. |
| WO2012101062A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses |
| WO2012162254A1 (en) * | 2011-05-23 | 2012-11-29 | Elan Pharmaceuticals, Inc. | Inhibitors of lrrk2 kinase activity |
| NO2714752T3 (e) * | 2014-05-08 | 2018-04-21 |
-
2017
- 2017-03-20 PE PE2018001829A patent/PE20181895A1/es not_active Application Discontinuation
- 2017-03-20 CN CN201780017874.XA patent/CN108884084A/zh active Pending
- 2017-03-20 AU AU2017237394A patent/AU2017237394A1/en not_active Abandoned
- 2017-03-20 TW TW106109172A patent/TW201808939A/zh unknown
- 2017-03-20 CA CA3017035A patent/CA3017035A1/en not_active Abandoned
- 2017-03-20 JP JP2018549311A patent/JP2019512512A/ja active Pending
- 2017-03-20 US US16/086,742 patent/US20190099421A1/en not_active Abandoned
- 2017-03-20 SG SG11201806982PA patent/SG11201806982PA/en unknown
- 2017-03-20 WO PCT/EP2017/056592 patent/WO2017162605A1/en not_active Ceased
- 2017-03-20 MX MX2018011283A patent/MX2018011283A/es unknown
- 2017-03-20 MA MA043733A patent/MA43733A/fr unknown
- 2017-03-20 BR BR112018068347A patent/BR112018068347A2/pt not_active IP Right Cessation
- 2017-03-20 KR KR1020187030086A patent/KR20180127419A/ko not_active Withdrawn
- 2017-03-20 EP EP17712123.3A patent/EP3433251A1/en not_active Withdrawn
- 2017-03-21 AR ARP170100697A patent/AR107937A1/es unknown
-
2018
- 2018-09-06 IL IL261648A patent/IL261648A/en unknown
- 2018-09-18 DO DO2018000197A patent/DOP2018000197A/es unknown
- 2018-10-12 CO CONC2018/0010951A patent/CO2018010951A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2018000197A (es) | 2018-10-15 |
| EP3433251A1 (en) | 2019-01-30 |
| KR20180127419A (ko) | 2018-11-28 |
| AR107937A1 (es) | 2018-06-28 |
| AU2017237394A1 (en) | 2018-11-01 |
| MX2018011283A (es) | 2019-05-27 |
| WO2017162605A1 (en) | 2017-09-28 |
| CN108884084A (zh) | 2018-11-23 |
| US20190099421A1 (en) | 2019-04-04 |
| BR112018068347A2 (pt) | 2019-01-15 |
| JP2019512512A (ja) | 2019-05-16 |
| CO2018010951A2 (es) | 2018-10-22 |
| PE20181895A1 (es) | 2018-12-11 |
| TW201808939A (zh) | 2018-03-16 |
| CA3017035A1 (en) | 2017-09-28 |
| IL261648A (en) | 2018-10-31 |
| SG11201806982PA (en) | 2018-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44225A (fr) | Sulfonylurées et composés apparentés et leur utilisation | |
| EP3265113A4 (en) | ANTI-LRB ANTIBODIES AND THEIR USE FOR THE DETECTION AND TREATMENT OF CANCER | |
| MA47440A (fr) | Sulfonylurées, composés apparentés, et leur utilisation | |
| MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
| MA39960A (fr) | Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer | |
| EP3307876A4 (en) | MODIFIED NK-92 CELLS FOR THE TREATMENT OF CANCER | |
| EP3370726A4 (en) | USE OF TLR8 AGONISTS FOR CANCER TREATMENT | |
| PL3265053T3 (pl) | Sposoby leczenia skóry | |
| MA45613A (fr) | Composés polycycliques-carbamoylpyridones et leur utilisation pharmaceutique | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| MA43364A (fr) | Composés d'alcènes tétrasubstitués et leur utilisation | |
| MA45709A (fr) | Composés diazahétérobicycliques substitués et leur utilisation | |
| EP3288592A4 (en) | USE OF CANNABIDIOL FOR THE TREATMENT OF CHILDREN'S SPAS | |
| EP3148536C0 (en) | Pharmaceutical combinations for treating cancer | |
| EP3411035A4 (en) | AMINOTHIAZONE COMPOUNDS AND USE THEREOF | |
| EP3317274A4 (en) | USE OF CHLOROQUIN AND CLEMIZOL COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY AND CANCER DISEASES | |
| EP3389645A4 (en) | COMBINATIONS FOR TREATING CANCER | |
| EP3250035A4 (en) | COMPOUNDS AND THEIR USE AS BACE-1 INHIBITORS | |
| MA71411A (fr) | Polythérapie pour le traitement de tumeurs malignes | |
| EP3359255A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | |
| EP3589659A4 (en) | COMPOUNDS AND USES FOR TREATMENT OF CANCER | |
| MA43570A (fr) | Thérapie génique pour traiter l'hypercholestérolémie familiale | |
| MA45113A (fr) | Composés mic-1 et leur utilisation | |
| EP2953938A4 (en) | FUNCTIONALIZED BENZOPYRANE COMPOUNDS AND USE THEREOF | |
| EP3347025A4 (en) | METHOD AND COMPOSITIONS FOR CANCER TREATMENT |